Paper42488560
Senkyunolide I and Danshensu in combination ameliorate post-MI myocardial fibrosis by regulating TGF-β1/PAI-1 in mice and heart organoids.
Fan S and 8 others. Front Pharmacol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Senkyunolide I and Danshensu in combination ameliorate post-MI myocardial fibrosis by regulating TGF-β1/PAI-1 in mice and heart organoids. Papers, record 42488560. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42488560
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Senkyunolide I and Danshensu in combination ameliorate post-MI myocardial fibrosis by regulating TGF-β1/PAI-1 in mice and heart organoids.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23634167 | The efficacy of guanxinning injection in treating angina pectoris: systematic review and meta-analysis of randomized controlled trials. | Evid Based Complement Alternat Med | 2013 | https://conductscience.org/library/papers/23634167 | PubMed |
| 2 | 31513752 | PAI-1 Regulation of TGF-β1-induced Alveolar Type II Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages. | Am J Respir Cell Mol Biol | 2020 | https://conductscience.org/library/papers/31513752 | PubMed |
| 3 | 27340270 | The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. | Circ Res | 2016 | https://conductscience.org/library/papers/27340270 | PubMed |
| 4 | 21927575 | Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. | Int J Biol Sci | 2011 | https://conductscience.org/library/papers/21927575 | PubMed |
| 5 | 20009036 | Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. | Blood | 2010 | https://conductscience.org/library/papers/20009036 | PubMed |
| 6 | 28520219 | Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis. | J Cell Biochem | 2018 | https://conductscience.org/library/papers/28520219 | PubMed |
| 7 | 31333457 | Ginkgo Flavonol Glycosides or Ginkgolides Tend to Differentially Protect Myocardial or Cerebral Ischemia-Reperfusion Injury via Regulation of TWEAK-Fn14 Signaling in Heart and Brain. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/31333457 | PubMed |
| 8 | 12860898 | Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. | Circulation | 2003 | https://conductscience.org/library/papers/12860898 | PubMed |
| 9 | 40953369 | Injectable BMSC-Based Extracellular Matrix-Mimicking Microtissue for Myocardial Infarction Repair. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/40953369 | PubMed |
| 10 | 40606601 | Qishen Yiqi alleviates periostin-mediated cardiac fibrosis and hypertrophy in Dahl hypertensive rat hearts and angiotensin II-induced cardiac organoids. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40606601 | PubMed |
| 11 | 31711127 | In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. | Cardiovasc Res | 2020 | https://conductscience.org/library/papers/31711127 | PubMed |
| 12 | 33307092 | Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. | J Mol Cell Cardiol | 2021 | https://conductscience.org/library/papers/33307092 | PubMed |
| 13 | 26632165 | Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction. | J Atheroscler Thromb | 2016 | https://conductscience.org/library/papers/26632165 | PubMed |
| 14 | 37110869 | Senkyunolide I: A Review of Its Phytochemistry, Pharmacology, Pharmacokinetics, and Drug-Likeness. | Molecules | 2023 | https://conductscience.org/library/papers/37110869 | PubMed |
| 15 | 35016208 | European Society of Cardiology: cardiovascular disease statistics 2021. | Eur Heart J | 2022 | https://conductscience.org/library/papers/35016208 | PubMed |
| 16 | 38819335 | Cardiac Magnetic Resonance Evaluation of LV Remodeling Post-Myocardial Infarction: Prognosis, Monitoring and Trial Endpoints. | JACC Cardiovasc Imaging | 2024 | https://conductscience.org/library/papers/38819335 | PubMed |
| 17 | 35563692 | Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction. | Cells | 2022 | https://conductscience.org/library/papers/35563692 | PubMed |
| 18 | 34446706 | Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. | Nat Commun | 2021 | https://conductscience.org/library/papers/34446706 | PubMed |
| 19 | 35461253 | Targeting TGF-β signal transduction for fibrosis and cancer therapy. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35461253 | PubMed |
| 20 | 35143754 | 2,5-Dimethylcelecoxib attenuates cardiac fibrosis caused by cryoinjury-induced myocardial infarction by suppressing the fibroblast-to-myofibroblast transformation via inhibition of the TGF-β signaling pathway. | Biochem Pharmacol | 2022 | https://conductscience.org/library/papers/35143754 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42488560
GET https://conductscience.org/api/papers/v1/42488560/references?page=2